Tags

Type your tag names separated by a space and hit enter

Bisphosphonates in the treatment of malignant bone disease.
Annu Rev Med. 1999; 50:237-48.AR

Abstract

Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents were shown effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies have been initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent large randomized double-blind studies show the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

Authors+Show Affiliations

Division of Hematology-Oncology, West Los Angeles Veterans Administration Medical Center, California, USA. BERENSON.JAMES@WEST-LA.VA.GOVNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10073275

Citation

Berenson, J R., and A Lipton. "Bisphosphonates in the Treatment of Malignant Bone Disease." Annual Review of Medicine, vol. 50, 1999, pp. 237-48.
Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 1999;50:237-48.
Berenson, J. R., & Lipton, A. (1999). Bisphosphonates in the treatment of malignant bone disease. Annual Review of Medicine, 50, 237-48.
Berenson JR, Lipton A. Bisphosphonates in the Treatment of Malignant Bone Disease. Annu Rev Med. 1999;50:237-48. PubMed PMID: 10073275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bisphosphonates in the treatment of malignant bone disease. AU - Berenson,J R, AU - Lipton,A, PY - 1999/3/12/pubmed PY - 1999/3/12/medline PY - 1999/3/12/entrez SP - 237 EP - 48 JF - Annual review of medicine JO - Annu Rev Med VL - 50 N2 - Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents were shown effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies have been initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent large randomized double-blind studies show the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma. SN - 0066-4219 UR - https://www.unboundmedicine.com/medline/citation/10073275/Bisphosphonates_in_the_treatment_of_malignant_bone_disease_ L2 - https://arjournals.annualreviews.org/doi/10.1146/annurev.med.50.1.237?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -